Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome with Eluxadoline

The Food and Drug Administration approved eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome despite cases of pancreatitis in early-stage trials. We investigated the frequency of pancreatitis attributed to eluxadoline in post-marketing surveillance.

http://ift.tt/2vnW4A1